RIYADH, SAUDI ARABIA – Media OutReach Newswire – 30 September 2024 – This past Saturday, the Annual Financial Services Forum in Riyadh successfully convened regulatory and industry leaders to discuss the future of the Saudi financial landscape. Hosted by j. awan & partners, the forum emphasized key strategies to enhance Saudi Arabia’s position as a global financial […]
رونان، مونتريال , Oct. 02, 2024 (GLOBE NEWSWIRE) — أعلنت اليوم شركة Montana Technologies Corporation، المدرجة في بورصة ناسداك تحت الرمز (AIRJ)، والمطورة لتقنية AirJoule® التحويلية لتوليد مياه الغلاف الجوي، عن تأسيس أول مكتب دولي لها في دولة الإمارات العربية المتحدة لتسريع نشر تقنية AirJoule® في المنطقة. صرّح رئيس شركة Montana Technologies، السيد Ramdas Rao، قائلاً: “سيساعدنا إنشاء مكتب في الإمارات العربية المتحدة […]
KUWAIT CITY, KUWAIT – Media OutReach Newswire – 2 October 2024 – Novo Nordisk Gulf, a leading global healthcare company, has been recognized as one of the Best Places to Work for 2024 across Kuwait, Qatar, Bahrain, and Oman. This certification highlights the company’s dedication to fostering a supportive, innovative, and inclusive work environment for its employees while remaining […]
New Solution Simplifies Insurance Carriers’ Payments Delivering Secure Transaction Capabilities as Part of the Proven Duck Creek Platform BOSTON, Oct. 02, 2024 (GLOBE NEWSWIRE) — Duck Creek Technologies, the intelligent solutions provider defining the future of property and casualty (P&C) and general insurance, today introduced its latest insurance-focused payments solution, the Duck Creek Payments Facilitator. […]
First program to combine Recursion’s end-to-end suite of AI-enabled active learning modules, resulting in target identification to IND enabling studies in under 18 months Plan to initiate dosing of Phase 1/2 in Q4 2024 to evaluate REC-1245 in a biomarker enriched patient population, including patients with solid tumors and lymphoma SALT LAKE CITY, Oct. 02, […]
First program to combine Recursion’s end-to-end suite of AI-enabled active learning modules, resulting in target identification to IND enabling studies in under 18 months Plan to initiate dosing of Phase 1/2 in Q4 2024 to evaluate REC-1245 in a biomarker enriched patient population, including patients with solid tumors and lymphoma SALT LAKE CITY, Oct. 02, […]